Dublin, Nov. 09, 2017 -- The "From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?" report has been added to Research and Markets' offering.
Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making. The growth in these two models has had an impact on both revenue derived from internally developed products, as well as externalized drugs.
Key Topics Covered:
1 EXECUTIVE SUMMARY
2 OVERALL TRENDS
3 R&D INVESTMENT TRENDS
- Overall R&D Investment trends
- Peer set R&D investment trends
- R&D productivity
- Bibliography
4 BIG PHARMA LICENSING TRENDS
- Alliance volume and value
- In-licensing and out-licensing
- Phase trends
- Therapy area trends
- Bibliography
5 REVENUE EXTERNALIZATION TRENDS
- Higher volume of unpartnered drugs, but partnered candidates are growing faster
- Externalized revenue growth due to M&A, co-developed drugs, and acquired products
- Peer set externalized revenue trends
- Higher average per-drug revenue expected for externalized products
- Bibliography
6 APPENDIX
- Scope
- Methodology
For more information about this report visit https://www.researchandmarkets.com/research/f39gpt/from_randd
CONTACT: Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals
